• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Basis for Low-affinity hERG Potassium Channel Block by Sotalol.

作者信息

Zhang Yi Hong, Dempsey Christopher E, Hancox Jules C

机构信息

School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, UK.

School of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.

出版信息

J Pharmacol Pharmacother. 2017 Jul-Sep;8(3):130-131. doi: 10.4103/jpp.JPP_69_17.

DOI:10.4103/jpp.JPP_69_17
PMID:29081622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5642127/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc4/5642127/8dec81b03c20/JPP-8-130-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc4/5642127/76cb20fbbe5c/JPP-8-130-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc4/5642127/8dec81b03c20/JPP-8-130-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc4/5642127/76cb20fbbe5c/JPP-8-130-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adc4/5642127/8dec81b03c20/JPP-8-130-g002.jpg

相似文献

1
The Basis for Low-affinity hERG Potassium Channel Block by Sotalol.索他洛尔对人醚 - 去极化激活的钾通道（hERG）低亲和力阻断的机制
J Pharmacol Pharmacother. 2017 Jul-Sep;8(3):130-131. doi: 10.4103/jpp.JPP_69_17.
2
Probing the interaction between inactivation gating and Dd-sotalol block of HERG.探究HERG失活门控与D-索他洛尔阻断之间的相互作用。
Circ Res. 2000 Nov 24;87(11):1012-8. doi: 10.1161/01.res.87.11.1012.
3
Additive effects of ziprasidone and D,L-sotalol on the action potential in rabbit Purkinje fibres and on the hERG potassium current.齐拉西酮与D,L-索他洛尔对兔浦肯野纤维动作电位及人ether-à-go-go相关基因（hERG）钾电流的相加作用。
J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):115-22. doi: 10.1016/j.vascn.2005.04.001.
4
CAVIN1-Mediated hERG Dynamics: A Novel Mechanism Underlying the Interindividual Variability in Drug-Induced Long QT.CAVIN1介导的hERG动力学：药物诱导长QT间期个体间变异性的一种新机制。
Circulation. 2024 Aug 13;150(7):563-576. doi: 10.1161/CIRCULATIONAHA.123.063917. Epub 2024 Apr 29.
5
Whole-Cell Configuration of the Patch-Clamp Technique in the hERG Channel Assay.全细胞模式下的 hERG 通道分析中的膜片钳技术配置。
Curr Protoc. 2024 Feb;4(2):e959. doi: 10.1002/cpz1.959.
6
Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential.评价潜在致心律失常作用：多非利特、西沙必利、索他洛尔、特非那定和维拉帕米对 hERG 和内源性 IKr 电流以及心脏动作电位的影响比较。
Toxicol Sci. 2019 Apr 1;168(2):365-380. doi: 10.1093/toxsci/kfy299.
7
Pharmacophore modeling for hERG channel facilitation.配体药效团模型构建用于 hERG 通道促进。
Biochem Biophys Res Commun. 2012 Feb 3;418(1):161-6. doi: 10.1016/j.bbrc.2011.12.153. Epub 2012 Jan 8.
8
Inhibition of Human Ether-A-Go-Go-Related Gene (hERG) Potassium Current by the Novel Sotalol Analogue, Soestalol.新型索他洛尔类似物索斯洛尔对人 Ether-A-Go-Go-Related Gene (hERG) 钾电流的抑制作用。
JACC Clin Electrophysiol. 2020 Jul;6(7):756-759. doi: 10.1016/j.jacep.2020.05.037.
9
The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents.高细胞外钾对抗心律失常药物抑制 IKr 的影响。
Cardiology. 2007;108(1):18-27. doi: 10.1159/000095596. Epub 2006 Sep 8.
10
Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.维拉帕米对HERG钾通道的阻滞机制及结合域的鉴定
Circ Res. 1999 May 14;84(9):989-98. doi: 10.1161/01.res.84.9.989.

引用本文的文献

1
Pediatric antiarrhythmics and toxicity: A clinical review.儿科抗心律失常药物与毒性：临床综述
J Am Coll Emerg Physicians Open. 2024 Feb 15;5(1):e13090. doi: 10.1002/emp2.13090. eCollection 2024 Feb.
2
Structural modeling of hERG channel-drug interactions using Rosetta.使用Rosetta对人乙醚-a-去极化相关基因（hERG）通道-药物相互作用进行结构建模。
Front Pharmacol. 2023 Nov 14;14:1244166. doi: 10.3389/fphar.2023.1244166. eCollection 2023.
3
Congenital Heart Disease: The State-of-the-Art on Its Pharmacological Therapeutics.先天性心脏病：其药物治疗的最新进展

本文引用的文献

1
Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.雷诺嗪对人乙醚 - 去极化相关基因（hERG）钾通道的抑制作用：药物与通道孔的相互作用以及对失活突变体效力的降低
J Mol Cell Cardiol. 2014 Sep;74(100):220-30. doi: 10.1016/j.yjmcc.2014.05.013. Epub 2014 May 27.
2
Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block.评估 hERG 孔模型作为药物对接模板的实验约束：药物阻断背景下的失活状态。
J Chem Inf Model. 2014 Feb 24;54(2):601-12. doi: 10.1021/ci400707h. Epub 2014 Feb 6.
3
J Cardiovasc Dev Dis. 2022 Jun 26;9(7):201. doi: 10.3390/jcdd9070201.
4
High-Throughput Chemical Screening and Structure-Based Models to Predict hERG Inhibition.用于预测hERG抑制的高通量化学筛选和基于结构的模型
Biology (Basel). 2022 Jan 28;11(2):209. doi: 10.3390/biology11020209.
5
Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline.通过多尺度建模管道研究 d-和 l-索他洛尔致心律失常倾向的分子决定因素。
J Mol Cell Cardiol. 2021 Sep;158:163-177. doi: 10.1016/j.yjmcc.2021.05.015. Epub 2021 May 29.
6
Calculation of absolute binding free energies between the hERG channel and structurally diverse drugs.计算 hERG 通道与结构多样的药物之间的绝对结合自由能。
Sci Rep. 2019 Nov 12;9(1):16586. doi: 10.1038/s41598-019-53120-6.
The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
人乙醚-去极化相关基因（hERG）钾通道与药物诱发尖端扭转型室速的hERG筛查
Pharmacol Ther. 2008 Aug;119(2):118-32. doi: 10.1016/j.pharmthera.2008.05.009. Epub 2008 Jun 18.
4
Molecular determinants of HERG channel block.HERG通道阻滞的分子决定因素。
Mol Pharmacol. 2006 May;69(5):1709-16. doi: 10.1124/mol.105.020990. Epub 2006 Feb 10.
5
A structural basis for drug-induced long QT syndrome.药物诱导性长QT综合征的结构基础。
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12329-33. doi: 10.1073/pnas.210244497.
6
Comparison of binding to rapidly activating delayed rectifier K+ channel, IKr, and effects on myocardial refractoriness for class III antiarrhythmic agents.III类抗心律失常药物与快速激活延迟整流钾通道IKr的结合比较及其对心肌不应期的影响。
J Cardiovasc Pharmacol. 1995 Feb;25(2):336-40. doi: 10.1097/00005344-199502000-00021.